Who Really Owns Novo Nordisk and Its Blockbuster Drugs?
If you tried to buy Novo Nordisk today, you couldn’t. This isn’t about the company’s market capitalization, which recently hovered above half a trillion dollars. Instead, it’s about the unique legal framework governing the company. Novo Nordisk, the maker of Ozempic, Wegovy, and roughly one-third of the world’s insulin supply, is controlled by an entity that has no shareholders, cannot be acquired, cannot go public, and cannot be liquidated in any conventional sense. In fact, the controlling body does not have an “owner” in the usual way we understand the term.
So, what exactly lies behind one of the most valuable pharmaceutical products on the planet?
The Dual-Share Structure of Novo Nordisk
While Novo Nordisk is a publicly listed company trading on both the Copenhagen and New York Stock Exchanges, what you buy as a regular investor are B-shares. These B-shares carry only one-tenth of the voting rights compared to the A-shares. According to Britannica’s corporate history, the A-shares are almost exclusively held by Novo Holdings, which itself is fully owned by the Novo Nordisk Foundation.
Recent disclosures, compiled in Yahoo Finance’s Company of the Year analysis, reveal that Novo Holdings holds about 28% of Novo Nordisk’s total share capital. However, because these shares are predominantly the high-voting A-shares, Novo Holdings controls roughly 77% of the voting power at shareholder meetings. This control means any significant decision—be it a takeover, strategic shift, or dividend change—requires the approval of the Novo Nordisk Foundation. Public shareholders can raise objections, but they cannot outvote the Foundation.
Crucially, the Foundation’s founding charter explicitly forbids the sale of these A-shares. They have never been traded, cannot be traded, and are locked away indefinitely.
For a detailed visual explanation of this structure, a video is available that breaks down how Ozempic operates: Click here to watch it.
Understanding the Enterprise Foundation Model
The Novo Nordisk Foundation is neither a family trust nor a traditional charity as commonly understood. Legally, in Denmark, it is an “erhvervsdrivende fond,” which translates to an industrial or enterprise foundation. This legal form is quite rare globally. As explained in The Spectator’s analysis, an industrial foundation is a self-governing entity with no shareholders, members, or owners. It exists solely to fulfill the purposes specified in its founding charter, and its board is legally bound to adhere strictly to that charter.
For the Novo Nordisk Foundation, the charter mandates two primary objectives: maintaining and supporting the commercial activities of Novo Nordisk and Novozymes, and distributing the wealth generated to scientific, humanitarian, and social causes. The foundation cannot be sold, acquired, or dissolved except under extraordinary legal conditions that are virtually never met. Revenues from the sales of drugs like Ozempic either get reinvested into the companies or flow out as grants and funding for research, hospitals, universities, and public-benefit initiatives throughout Denmark and beyond.
The scale of this foundation is staggering. The latest disclosures show that the Novo Nordisk Foundation controls assets exceeding €100 billion, making it the world’s largest philanthropic foundation, surpassing even the Bill & Melinda Gates Foundation. Unlike many private foundations that gradually spend down their endowments, this foundation continuously generates dividends from a thriving pharmaceutical business.
The Danish Industrial Foundation Model in Context
This ownership model is not unique to Novo Nordisk but is a distinctive feature of the Danish economy, often unnoticed outside Scandinavia. Other major Danish companies such as Carlsberg, controlled by the Carlsberg Foundation; Maersk, under the A.P. Møller Foundation; Lundbeck, governed by the Lundbeck Foundation; and Vestas, partially owned by foundations, all follow similar structures. Germany also has comparable models, including Bosch and Bertelsmann with their respective foundations. IKEA, while Swedish, is owned through a Dutch foundation with similar legal restrictions.
Academically referred to as “foundation ownership” or “fondsejerskab,” this model has been studied extensively, including research by Copenhagen Business School. Findings suggest companies under foundation ownership exhibit distinct behaviors: they accept slower returns, invest heavily in research, resist takeovers, and demonstrate greater longevity compared to typical publicly traded firms.
Critics argue this model resembles an industrial dynasty masked as philanthropy, while supporters highlight its role in keeping companies like Novo Nordisk Danish, research-focused, and shielded from the M&A waves that have fragmented much of the European pharmaceutical sector. Empirical evidence, though limited due to the small number of such companies, generally supports that foundation-owned firms outperform conventional firms over long horizons.
Implications for Ozempic and Beyond
The ownership structure has direct implications for Ozempic and semaglutide as a drug class. No individual or private equity group benefits from short-term profit maximization. There is no family or billionaire founder cashing in stock options, and no pressure from shareholders demanding rapid quarterly earnings growth. The A-shares controlling Novo Nordisk are held by an institution that cannot benefit personally from share price increases, as it has no conventional beneficiaries.
The Foundation’s financial activities are transparent. According to the Novo Nordisk Foundation’s official website, it distributed about 10.4 billion Danish kroner (approximately $1.5 billion USD) in grants during 2024. These funds support diabetes research globally, basic biomedical research at Danish universities, humanitarian projects, and expanding climate and biotech initiatives. Many of the world’s leading diabetes researchers have received Foundation support, and Danish academic buildings bear its name.
That said, Ozempic remains an expensive drug, especially in the United States, and the Foundation’s ownership structure has not resulted in significantly lower prices for patients paying out of pocket. However, instead of dividends flowing to shareholders or funding share buybacks, a significant portion of profits is funneled into perpetual research funding that is likely to outlast every current employee.
The Broader Significance of Ownerless Capitalism
The Novo Nordisk Foundation’s setup invites a fascinating thought experiment: What if more pharmaceutical companies were structured like this? Imagine profits from blockbuster drugs fueling permanent research endowments rather than flowing primarily to institutional investors or executives.
However, the Danish industrial foundation model depends on specific legal frameworks, tax treatments, and cultural norms that prioritize anchoring nationally important companies rather than selling them off. Attempts to replicate this ownership structure in countries like the United States and the United Kingdom have encountered resistance, as non-tradeable controlling shares clash with prevailing notions of shareholder democracy.
Still, Novo Nordisk serves as a compelling case study. It demonstrates that a pharmaceutical giant can thrive under the control of an entity with no legal owner. This form of “ownerless capitalism” challenges conventional wisdom and offers a unique model for balancing commercial success with long-term societal benefit.
In short, the answer to who owns Ozempic is legally and truly nobody. The Novo Nordisk Foundation simply stewards it.
Source: Here
